ARCUS BIOSCIENCES INC (RCUS:NYSE)
$26.15 -2.34 (-8.2134%)
Analysed ARCUS BIOSCIENCES INC (RCUS:NYSE) News Sources
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
06-08-2026
yahoo.com
Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism
08-08-2026
yahoo.com
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
26-08-2026
yahoo.com
Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary
06-08-2026
moby.co
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
05-08-2026
yahoo.com
Arcus Biosciences Q2 Earnings Call Highlights
09-08-2026
marketbeat.com
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
10-08-2026
yahoo.com
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript
13-08-2026
fool.com
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
14-08-2026
yahoo.com
Arcus Biosciences Announces New Employment Inducement Grants
09-09-2026
yahoo.com
What is the current price of ARCUS BIOSCIENCES INC (RCUS:NYSE)?
The current price of ARCUS BIOSCIENCES INC (RCUS:NYSE) is $26.15.
ARCUS BIOSCIENCES INC (RCUS:NYSE) absolute price change since previous trading day?
The absolute price change of ARCUS BIOSCIENCES INC (RCUS:NYSE) since the previous trading day is $-2.34.
ARCUS BIOSCIENCES INC (RCUS:NYSE) percentage price change since previous trading day?
The percentage price change of ARCUS BIOSCIENCES INC (RCUS:NYSE) since the previous trading day is -8.2134%.
What is the most recent average sentiment score for ARCUS BIOSCIENCES INC (RCUS:NYSE)?
The most recent average sentiment score for ARCUS BIOSCIENCES INC (RCUS:NYSE) is 71 out of 100.
What is the most recent average sentiment for ARCUS BIOSCIENCES INC (RCUS:NYSE)?
The most recent sentiment for ARCUS BIOSCIENCES INC (RCUS:NYSE) is .
SEC-8K** Filing Available For ARCUS BIOSCIENCES INC (RCUS:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.